Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the anti-varicella zoster virus agent netivudine

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 1, 1996, Pages 22-31

  Peck, Richard ^a   Wiggs, Rebecca ^b   Callaghan, Julia ^b   Wootton, Ray ^b   Crome, Peter ^b   Fraser, Ian ^b   Frick, Lloyd ^b   Posner, John ^b  

^a Wellcome Research Foundation   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 PROPYNYLURACIL; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG METABOLITE; FLUOROURACIL; NETIVUDINE; PLACEBO; UNCLASSIFIED DRUG; URACIL;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VARICELLA ZOSTER VIRUS;

AGED; ALKYNES; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; DIHYDROURACIL DEHYDROGENASE (NADP); DOSE-RESPONSE RELATIONSHIP, DRUG; HERPESVIRUS 3, HUMAN; HUMANS; OXIDOREDUCTASES; URACIL;

EID: 0030067723     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90020-X     Document Type: Article

References (22)

1. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency in dihydropyrimidine dehydrogenase: biochemical basis for familial pyridinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988;81: 47-51.
2. Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency a potentially more common pharmacogenetic syndrome. Cancer 1991;68:499-501.
3. Tuchman M, Stoeckeler JS, Kiang DT, O'Dea RF, Ramnaraine ML, Mirkin BL. Familial pyridinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 1985;313:245-9.
4. Fleming RA, Milano GA, Gaspard MH, et al. Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J Cancer 1993;29A:740-4.
5. Rahim SG, Trivedi N, Selway J, et al. 5-Alkynyl pyrimidine nucleosides as potent selective inhibitors of varicella-zoster virus. Antiviral Chem Chemother 1992;35:293-7.
6. Peck RW, Weatherley BC, Wootton R, Crome P, Holdich TAH, Posner J. Pharmacokinetics and tolerability of single oral doses of netivudine, a potent, new anti varicella-zoster virus agent, in healthy volunteers. Antimicrob Agents Chemother 1995;39:20-7.
7. Peck RW, Wootton R, Lee DR, Jackson HD, Posner J. The bioavailability and disposition of 1(-β-D-arabinofuranosyl)-5-(1-propynyl)uracil (netivudine), a potent, new anti-varicella zoster virus agent. Br J Clin Pharmacol 1995;39:143-9.
8. Peck RW, Crome P, Wood MJ, et al. Multiple dose netivudine, a potent anti-varicella zoster virus agent, in healthy elderly volunteers and patients with shingles. J Antimicrob Chemother [In press].
9. Wood MJ, McKendrick MW, Bannister B, Mandal BK, Peck RW, Crooks RJ. Pharmacokinetics and safety of 882C87 in patients with herpes zoster. J Med Virol 1993;suppl 1:154-7.
10. Porter DJT, Chestnut WG, Merrill BM, Spector T. Mechanism based inactivation of dihydropyrimidine dehydrogenase by 5- ethynyluracil. J Biol Chem 1992; 267:5236-42.
11. Desranges CD, Razaka G De Clerq E, et al. Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumour activity of 5-fluorouracil in rats and leukaemic mice. Cancer Res 1986;46:1094-101.
12. Ben-Efraim S, Shoval S, De Clerq E. Enhancing effect of bromovinyluracil on antitumour activity of 5-fluorouracil in mice bearing MOPC-315 plasmacytomas. Br J Cancer 1986;54:847-51.
13. Iigo M, Araki E, Nakajima Y, Hoshi A, De Clerq E. Enhancing effect of bromovinyluracil on antitumour activity of 5-fluorouracil against adenocarcinoma 755 in mice: increased therapeutic index and correlation with increased plasma 5-fluorouracil levels. Biochem Pharmacol 1988;37:1609-13.
14. Baccanari DP, Davis ST, Knick VC, Spector T. 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumour efficacy of 5-fluorouracil. Proc Natl Acad Sci 1993;90:11064-8.
15. Cao S, Rustum YM, Spector T. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 1994;54:1507-10.
16. Spector T, Porter DJT, Nelson DJ, et al. 5-Ethynyluracil (776C85), a modulator of the therapeutic activity of 5-fluorouracil. Drugs Future 1994;19: 565-71.
17. Spector T, Cao S, Rustum YM, Harrington JA, Porter DJT. Attenuation of the antitumour activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil. Cancer Res 1995;55:1239-41.
18. Davis ST, Joyner SS, Baccanari DP, Spector T. 5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs. Biochem Pharmacol 1994;48:233-6.
19. Buick A. Fook-Sheung CTC. Determination of 1(-β-D-arabinofuranosyl)-5-propynyluracil and a metabolite, 5-propynyluracil, in plasma using ASTED (automated sequential trace enrichment of dialysates) combined on-line with high-performance liquid chromatography. J Chromatogr 1993;617:65-70.
20. Cooper JDH, Fook-Sheung CTC, Buick A. The determination of the nucleoside 882C and its metabolite 248U in urine using an automated heart cutting ASTED configuration and high pressure liquid chromatography. J Chromatogr 1994;652:15-21.
21. Khor SP, Lucas S, Schilsky R, et al. A phase I pharmacokinetic study of 5-ethynyluracil plus 5-fluorouracil in cancer patients with solid tumors [Abstract]. Proc Am Assoc Cancer Res 1995;36:1439.
22. Wasternack C. Degradation of pyrimidines and pyrimidine analogs - pathways and mutual influences. Pharmacol Ther 1980;8:629-51.